Pre-made Ivicentamab benchmark antibody ( Whole mAb, anti-CD37;CD37 therapeutic antibody, Anti-GP52-40/TSPAN26;GP52-40/TSPAN26 Antibody) for drug discovery and mechanism of action (MOA) research
Cat No.: GMP-Bios-ab-673
Pre-Made Ivicentamab biosimilar, Whole mAb, Anti-CD37;CD37 Antibody: Anti-GP52-40/TSPAN26;GP52-40/TSPAN26 therapeutic antibody is a biosimilar expressed by mammalian cell line as a benchmark reference therapeutic antibody for biological drug disovery items including cell culture, assay development, animal model development, PK/PD model development (Pharmacokinetics & Pharmacodynamic) and mechanism of action (MOA) research.
Order information
* GeneMedi provides NON-PROFIT PRICE to support Academic research. Please click inquiry for product quotation. → Inquiry
Catalog No. | Package | Price(In USD) | Qty (Quantity) | Sum(In USD) |
---|---|---|---|---|
GMP-Bios-ab-673-1mg | 1mg | Inquiry | ||
GMP-Bios-ab-673-10mg | 10mg | Inquiry | ||
GMP-Bios-ab-673-100mg | 100mg | Inquiry | ||
GMP-Bios-ab-673-xmg | >100mg | Inquiry | ||
Shipping Cost: | 760.00 | |||
Total: | ||||
Description
Products Name (INN Index) | Pre-Made Ivicentamab biosimilar, Whole mAb, Anti-CD37;CD37 Antibody: Anti-GP52-40/TSPAN26;GP52-40/TSPAN26 therapeutic antibody |
INN Name | Ivicentamab |
Target | CD37;CD37 |
Format | Bispecific Whole mAb |
Derivation | Humanized |
Species Reactivity | Human |
CH1 Isotype | IgG1;IgG1 |
VD LC | Kappa;Kappa |
Highest_Clin_Trial (Jan '20) | Phase-I/II |
Est. Status | Active |
100% SI Structure | None;None |
99% SI Structure | None;None |
95-98% SI Structure | None;None |
Year Proposed | 2021 |
Year Recommended | na |
Companies | Genmab |
Conditions Approved | na |
Conditions Active | B cell Lymphoma |
Conditions Discontinued | na |
Development Tech | DuoBody |
- GENEMEDI
- Email: [email protected] [email protected]
- Telephone: +86-21-50478399 Fax: 86-21-50478399
- Privacy Policy
- TECHNICAL SUPPORT
- Product FAQs
- Technical manuals
- Publications
- Email: [email protected]
<